The glow could someday help us use cancer drugs more efficiently.
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography (PET) scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.
The technique uses PET imaging of a synthesized radiolabeled protein that locks on to tumor cells, letting researchers visually follow where a so-called checkpoint inhibitor drug binds to a tumor as it disperses. “This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person,” says Sridhar Nimmagadda, Ph.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine and a member of the Sidney Kimmel Comprehensive Cancer Center. If more tests in animals and humans confirm the scan’s precision and safety, its use could streamline cancer therapy by enhancing doctors’ ability to tailor therapy, help determine the therapeutic dose of a drug, and avoid or stop treatments that are not effective, Nimmagadda says.
The study is described in the Feb. 1 issue of The Journal of Clinical Investigation.
Use of checkpoint inhibitors is a type of cancer therapy designed to help the immune system recognize cancer cells as dangerous and target them for destruction. Tumors often hijack these natural protective systems, allowing the tumors to masquerade as healthy tissues. The programmed death ligand 1 (PD-L1) is one such checkpoint target, and it is currently the backbone of immune checkpoint therapies, with three very expensive drugs—atezolizumab, avelumab and durvalumab—now approved by the U.S. Food and Drug Administration (FDA).
However, the Johns Hopkins researchers say, their use is often a shot in the dark, because it’s difficult to predict or quickly track how much PD-L1 is expressed in different tumors and how efficiently those drugs bind to PD-L1 receptors at the tumor in patients.
The research team created a specialized radiolabeled small protein, or peptide, in the lab that binds to PD-L1, which facilitates marking the receptor with a radiotracer that can be seen with PET imaging.
Using their radiolabeled peptide, the researchers investigated whether they could follow the interaction between the drug and the PD-L1 checkpoint protein to measure how thoroughly and quickly the inhibitor drugs bound to this important target in real time.
First, in tests in cells grown in the lab, the researchers confirmed that their radiolabeled peptide would not alter or interfere with the immunotherapy drugs. They said multiple tests showed the radiolabeled peptide bound to PD-L1 with less vigor and could not push off the bound drug. This ability, in theory, would allow the radiolabeled peptide to serve as an efficient marker for PD-L1 proteins still waiting to receive treatment.
They next sought to verify this effect in animals. The researchers treated mice that had implanted human lung tumors with a single dose of atezolizumab—a drug that fights cancer by binding to PD-L1—and waited 24 hours, allowing the checkpoint inhibitor to bind to PD-L1. They followed this treatment with the radiolabeled peptide and PET imaging.
When the mice in the experimental group receiving atezolizumab were compared to controls that received only a saline injection, the researchers found a 77 percent reduction in unoccupied PD-L1 levels in the tumor, indicating that treatment reached many of the PD-L1 proteins.
“The remaining areas indicate parts of the tumor that the immunotherapy didn’t reach,” says Nimmagadda, who is a member of the Institute for Basic Biomedical Sciences at the Johns Hopkins University School of Medicine. “In human patients, this could give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly.”
The researchers then tested whether they could use their method to measure changes in PD-L1 receptor levels on a tumor.
Again using mice with human lung tumors, the researchers treated the rodents with a drug that increases PD-L1 levels in tumor cells. This treatment was followed with the radiolabeled peptide. Upon imaging these mice with PET, they found that the radiotracer levels were 65 percent higher than in control animals with normal levels of PD-L1 receptors. These studies showed that changes in PD-L1 levels could be measured without a biopsy during immune checkpoint therapy.
Additionally, in chemical structure studies of the peptide, the researchers found that peptide binding to PD-L1 is similar to each of the immunotherapy drugs the FDA has approved, suggesting that the same performance observed in their experiments would likely translate to treatments with other immune checkpoint drugs.
“These results represent a necessary initial step toward finding safe, effective and personalized doses of immunotherapy,” says Nimmagadda.
The researchers are working on improving the technique, and they plan to begin clinical trials this year.
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Potential new immunotherapy for critical COVID-19on June 4, 2020 at 4:57 pm
Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).
- Macrophages enter CAR immunotherapyon June 4, 2020 at 8:16 am
To overcome this challenge, Michael Klichinsky in the laboratory of Saar Gill at the University of Pennsylvania and colleagues have transduced CARs into macrophages (CAR-Ms) to show that CAR-Ms could ...
- DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020on June 4, 2020 at 7:30 am
DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital ...
- PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Canceron June 4, 2020 at 7:05 am
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® ...
- Immunotherapy Drugs Report (2020-2025) The Demand For The Market Will Drastically Increase In The FutureMarketon June 2, 2020 at 11:05 pm
The global Immunotherapy Drugs market was valued at USD 108.39 billion in 2016 and is projected to reach USD 338.54 billion by 2025, growing at a CAGR of 13.49% from 2017 to 2025. Immunotherapy is in ...
- Cancer Immunotherapy Market to Reach USD 153.03 Billion by 2027 | Reports And Dataon June 2, 2020 at 6:27 am
The global cancer immunotherapy market is forecasted to reach USD 153.03 billion in 2027, according to a new report by Reports and Data. The global cancer immunotherapy market is growing at a substant ...
- Cancer Immunotherapy Study Identifies New Checkpoint Targets in Myeloid Cellson June 1, 2020 at 3:15 pm
Cancer immunotherapy could be improved by developing checkpoint inhibitors that target c-Rel, which promotes the generation of suppressive myeloid cells ...
- New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trialon May 31, 2020 at 9:53 am
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health ...
- FDA approves Roche immunotherapy cocktail in liver canceron May 29, 2020 at 5:17 pm
Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer ...
- Infection risk up in month after CAR T-cell immunotherapyon May 29, 2020 at 9:52 am
For children and young adults receiving CD19 chimeric antigen receptor (CAR) T-cell infusion (CTI), infection rates increase in the first month after treatment and then decrease, according to a study ...
via Bing News